Evolus, Inc. (NASDAQ:EOLS – Get Rating) major shareholder Medytox Inc. sold 15,300 shares of the company’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $10.39, for a total transaction of $158,967.00. Following the completion of the transaction, the insider now owns 7,422,352 shares of the company’s stock, valued at approximately $77,118,237.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Medytox Inc. also recently made the following trade(s):
On Monday, August 1st, Medytox Inc. sold 26,000 shares of Evolus stock. The stock was sold at an average price of $13.28, for a total transaction of $345,280.00.
Evolus Price Performance
Shares of EOLS traded up $0.36 during mid-day trading on Monday, hitting $10.72. 413,834 shares of the company were exchanged, compared to its average volume of 513,900. Evolus, Inc. has a 1-year low of $5.06 and a 1-year high of $14.34. The stock has a market cap of $601.34 million, a price-to-earnings ratio of -7.60 and a beta of 2.01. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.36 and a current ratio of 2.60. The company has a 50 day moving average of $11.03 and a 200-day moving average of $11.29.
Institutional Trading of Evolus
Several large investors have recently bought and sold shares of the business. Legal & General Group Plc grew its stake in Evolus by 272.9% during the 2nd quarter. Legal & General Group Plc now owns 12,727 shares of the company’s stock valued at $148,000 after acquiring an additional 9,314 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Evolus by 65.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 148,484 shares of the company’s stock valued at $1,723,000 after acquiring an additional 58,943 shares in the last quarter. Prudential Financial Inc. grew its stake in Evolus by 1,215.2% during the 2nd quarter. Prudential Financial Inc. now owns 376,420 shares of the company’s stock valued at $4,366,000 after acquiring an additional 347,800 shares in the last quarter. Deerfield Management Company L.P. Series C grew its stake in Evolus by 195.5% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,632,751 shares of the company’s stock valued at $42,140,000 after acquiring an additional 2,403,517 shares in the last quarter. Finally, State Street Corp grew its stake in Evolus by 25.8% during the 2nd quarter. State Street Corp now owns 873,320 shares of the company’s stock valued at $10,131,000 after acquiring an additional 179,111 shares in the last quarter. Hedge funds and other institutional investors own 50.60% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC initiated coverage on shares of Evolus in a research report on Thursday, June 23rd. They set a “buy” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Evolus has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.